Luo Liangliang, Pan Yao, Chen Fang, Zhang Zhihong
School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang, China.
Jiangxi Provincial Key Laboratory of Disease Prevention and Public Health, Nanchang University, Nanchang, China.
Medicine (Baltimore). 2024 Dec 27;103(52):e40726. doi: 10.1097/MD.0000000000040726.
Alzheimer's disease (AD) is a neurodegenerative disease, and there have been no systematic studies of Polygonatum against Alzheimer's disease. Therefore, our study will elucidate the mechanism of Polygonatum against AD based on network pharmacology and molecular docking. The active ingredients and corresponding targets of Polygonatum were identified using the traditional Chinese medicine systematic pharmacology database and analysis platform. Disease targets of AD were retrieved from the therapeutic target database, Online Mendelian Inheritance in Man, GeneCards, and Disgenet databases. Using the STRING database, we constructed protein interaction networks and performed gene ontology functional enrichment analysis as well as Kyoto encyclopedia of genes and genomes pathway enrichment analysis on common targets. We then drew drug-component-target-pathway-disease network maps using Cytoscape 3.10.1 software and validated the molecular docking using AutoDock4. A total of 10 active ingredients and 108 common targets were screened from Polygonatum, 29 genes (including AKT1 and STAT3) were identified as core genes. According to gene ontology analysis, the core targets were found to be mainly involved in signal transduction, positive regulation of gene expression, negative regulation of the apoptotic process, and so on. The Kyoto encyclopedia of genes and genomes analysis revealed that the signaling pathways comprised pathways in cancer, pathways of neurodegeneration - multiple diseases, and PI3K-Akt signaling pathway. The molecular docking results indicated that 10 of active ingredients from Polygonatum exhibited strong binding affinity with the 6 core targets that were screened before. The activity of Polygonatum against AD could be attributed to the regulation of multiple biological effects via multi-pathways (pathways in cancer, pathways of neurodegeneration - multiple diseases, and PI3K-Akt signaling pathway). The binding activities were estimated as good level by molecular docking. These discoveries disclosed the multi-component, multi-target, and multi-pathway characteristics of Polygonatum against AD, providing a new strategy for such medical problem.
阿尔茨海默病(AD)是一种神经退行性疾病,目前尚未有关于黄精对阿尔茨海默病的系统研究。因此,我们的研究将基于网络药理学和分子对接阐明黄精抗AD的作用机制。利用中药系统药理学数据库和分析平台确定黄精的活性成分及其相应靶点。从治疗靶点数据库、《人类孟德尔遗传在线》、基因卡片和DisGeNET数据库中检索AD的疾病靶点。利用STRING数据库构建蛋白质相互作用网络,并对共同靶点进行基因本体功能富集分析以及京都基因与基因组百科全书通路富集分析。然后使用Cytoscape 3.10.1软件绘制药物-成分-靶点-通路-疾病网络图,并使用AutoDock4验证分子对接。从黄精中筛选出10种活性成分和108个共同靶点,确定29个基因(包括AKT1和STAT3)为核心基因。根据基因本体分析,发现核心靶点主要参与信号转导、基因表达的正调控、凋亡过程的负调控等。京都基因与基因组百科全书分析显示,信号通路包括癌症通路神经退行性变-多种疾病通路和PI3K-Akt信号通路。分子对接结果表明,黄精中的10种活性成分与之前筛选出的6个核心靶点表现出较强的结合亲和力。黄精抗AD的活性可能归因于通过多途径(癌症通路、神经退行性变-多种疾病通路和PI3K-Akt信号通路)调节多种生物学效应。通过分子对接评估结合活性为良好水平。这些发现揭示了黄精抗AD的多成分、多靶点和多途径特征,为解决此类医学问题提供了新策略。